Wedbush initiates coverage on Pharmacyclics (Nasdaq: PCYC) with an Outperform rating and a $5.50 fair value estimate.

The firm ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE